Single User License
INR 168725
Site License
INR 337450
Corporate User License
INR 506175

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015

Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 9

Glioblastoma Multiforme (GBM) Overview 10

Therapeutics Development 11

Glioblastoma Multiforme (GBM)-Therapeutics under Development by Companies 13

Glioblastoma Multiforme (GBM)-Therapeutics under Investigation by Universities/Institutes 27

Glioblastoma Multiforme (GBM)-Pipeline Products Glance 32

Glioblastoma Multiforme (GBM)-Products under Development by Companies 36

Glioblastoma Multiforme (GBM)-Products under Investigation by Universities/Institutes 53

Glioblastoma Multiforme (GBM)-Companies Involved in Therapeutics Development 57

Glioblastoma Multiforme (GBM)-Therapeutics Assessment 207

Drug Profiles 239

Glioblastoma Multiforme (GBM)-Recent Pipeline Updates 729

Glioblastoma Multiforme (GBM)-Dormant Projects 997

Glioblastoma Multiforme (GBM)-Discontinued Products 1007

Glioblastoma Multiforme (GBM)-Product Development Milestones 1010

Appendix 1019

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2015 42

Number of Products under Development for Glioblastoma Multiforme (GBM)-Comparative Analysis, H1 2015 43

Number of Products under Development by Companies, H1 2015 45

Number of Products under Development by Companies, H1 2015 (Contd..1) 46

Number of Products under Development by Companies, H1 2015 (Contd..2) 47

Number of Products under Development by Companies, H1 2015 (Contd..3) 48

Number of Products under Development by Companies, H1 2015 (Contd..4) 49

Number of Products under Development by Companies, H1 2015 (Contd..5) 50

Number of Products under Development by Companies, H1 2015 (Contd..6) 51

Number of Products under Development by Companies, H1 2015 (Contd..7) 52

Number of Products under Development by Companies, H1 2015 (Contd..8) 53

Number of Products under Development by Companies, H1 2015 (Contd..9) 54

Number of Products under Development by Companies, H1 2015 (Contd..10) 55

Number of Products under Development by Companies, H1 2015 (Contd..11) 56

Number of Products under Development by Companies, H1 2015 (Contd..12) 57

Number of Products under Investigation by Universities/Institutes, H1 2015 58

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 60

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 61

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 62

Comparative Analysis by Late Stage Development, H1 2015 63

Comparative Analysis by Clinical Stage Development, H1 2015 64

Comparative Analysis by Early Stage Development, H1 2015 65

Comparative Analysis by Unknown Stage Development, H1 2015 66

Products under Development by Companies, H1 2015 67

Products under Development by Companies, H1 2015 (Contd..1) 68

Products under Development by Companies, H1 2015 (Contd..2) 69

Products under Development by Companies, H1 2015 (Contd..3) 70

Products under Development by Companies, H1 2015 (Contd..4) 71

Products under Development by Companies, H1 2015 (Contd..5) 72

Products under Development by Companies, H1 2015 (Contd..6) 73

Products under Development by Companies, H1 2015 (Contd..7) 74

Products under Development by Companies, H1 2015 (Contd..8) 75

Products under Development by Companies, H1 2015 (Contd..9) 76

Products under Development by Companies, H1 2015 (Contd..10) 77

Products under Development by Companies, H1 2015 (Contd..11) 78

Products under Development by Companies, H1 2015 (Contd..12) 79

Products under Development by Companies, H1 2015 (Contd..13) 80

Products under Development by Companies, H1 2015 (Contd..14) 81

Products under Development by Companies, H1 2015 (Contd..15) 82

Products under Development by Companies, H1 2015 (Contd..16) 83

Products under Investigation by Universities/Institutes, H1 2015 84

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 85

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 86

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 87

Glioblastoma Multiforme (GBM)-Pipeline by AB Science, H1 2015 88

Glioblastoma Multiforme (GBM)-Pipeline by AbbVie Inc., H1 2015 89

Glioblastoma Multiforme (GBM)-Pipeline by Actelion Ltd, H1 2015 90

Glioblastoma Multiforme (GBM)-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 91

Glioblastoma Multiforme (GBM)-Pipeline by Actinogen Limited, H1 2015 92

Glioblastoma Multiforme (GBM)-Pipeline by Activartis Biotech GmbH, H1 2015 93

Glioblastoma Multiforme (GBM)-Pipeline by Aduro BioTech, Inc., H1 2015 94

Glioblastoma Multiforme (GBM)-Pipeline by Advanced Accelerator Applications SA, H1 2015 95

Glioblastoma Multiforme (GBM)-Pipeline by Advanced Cancer Therapeutics, H1 2015 96

Glioblastoma Multiforme (GBM)-Pipeline by Advenchen Laboratories, LLC, H1 2015 97

Glioblastoma Multiforme (GBM)-Pipeline by Agenus, Inc., H1 2015 98

Glioblastoma Multiforme (GBM)-Pipeline by AGY Therapeutics, Inc., H1 2015 99

Glioblastoma Multiforme (GBM)-Pipeline by Amal Therapeutics SA, H1 2015 100

Glioblastoma Multiforme (GBM)-Pipeline by Ambrx, Inc., H1 2015 101

Glioblastoma Multiforme (GBM)-Pipeline by Amgen Inc., H1 2015 102

Glioblastoma Multiforme (GBM)-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 103

Glioblastoma Multiforme (GBM)-Pipeline by AngioChem Inc., H1 2015 104

Glioblastoma Multiforme (GBM)-Pipeline by Apogenix GmbH, H1 2015 105

Glioblastoma Multiforme (GBM)-Pipeline by Argon Pharma S.L., H1 2015 106

Glioblastoma Multiforme (GBM)-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 107

Glioblastoma Multiforme (GBM)-Pipeline by Astellas Pharma Inc., H1 2015 108

Glioblastoma Multiforme (GBM)-Pipeline by AstraZeneca Plc, H1 2015 109

Glioblastoma Multiforme (GBM)-Pipeline by Axelar AB, H1 2015 110

Glioblastoma Multiforme (GBM)-Pipeline by Bexion Pharmaceuticals, LLC., H1 2015 111

Glioblastoma Multiforme (GBM)-Pipeline by biOasis Technologies Inc., H1 2015 112

Glioblastoma Multiforme (GBM)-Pipeline by BioCancell Ltd, H1 2015 113

Glioblastoma Multiforme (GBM)-Pipeline by Biomar Microbial Technologies, H1 2015 114

Glioblastoma Multiforme (GBM)-Pipeline by Bioncotech Therapeutics S.L., H1 2015 115

Glioblastoma Multiforme (GBM)-Pipeline by Biovista Inc., H1 2015 116

Glioblastoma Multiforme (GBM)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 117

Glioblastoma Multiforme (GBM)-Pipeline by Boston Biomedical, Inc., H1 2015 118

Glioblastoma Multiforme (GBM)-Pipeline by Bristol-Myers Squibb Company, H1 2015 119

Glioblastoma Multiforme (GBM)-Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 120

Glioblastoma Multiforme (GBM)-Pipeline by Cavion LLC, H1 2015 121

Glioblastoma Multiforme (GBM)-Pipeline by Celgene Corporation, H1 2015 122

Glioblastoma Multiforme (GBM)-Pipeline by Celldex Therapeutics, Inc., H1 2015 123

Glioblastoma Multiforme (GBM)-Pipeline by Cellectis S.A., H1 2015 124

Glioblastoma Multiforme (GBM)-Pipeline by Celltrion, Inc., H1 2015 125

Glioblastoma Multiforme (GBM)-Pipeline by Celsion Corporation, H1 2015 126

Glioblastoma Multiforme (GBM)-Pipeline by ChemoCentryx, Inc., H1 2015 127

Glioblastoma Multiforme (GBM)-Pipeline by CLL Pharma, H1 2015 128

Glioblastoma Multiforme (GBM)-Pipeline by Cold Genesys, Inc., H1 2015 129

Glioblastoma Multiforme (GBM)-Pipeline by CTI BioPharma Corp., H1 2015 130

Glioblastoma Multiforme (GBM)-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 131

Glioblastoma Multiforme (GBM)-Pipeline by CureTech Ltd., H1 2015 132

Glioblastoma Multiforme (GBM)-Pipeline by CytomX Therapeutics, Inc., H1 2015 133

Glioblastoma Multiforme (GBM)-Pipeline by CytoVac A/S, H1 2015 134

Glioblastoma Multiforme (GBM)-Pipeline by CytRx Corporation, H1 2015 135

Glioblastoma Multiforme (GBM)-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 136

Glioblastoma Multiforme (GBM)-Pipeline by DEKK-TEC, Inc., H1 2015 137

Glioblastoma Multiforme (GBM)-Pipeline by Delenex Therapeutics AG, H1 2015 138

Glioblastoma Multiforme (GBM)-Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 139

Glioblastoma Multiforme (GBM)-Pipeline by DiscoveryBiomed, Inc., H1 2015 140

Glioblastoma Multiforme (GBM)-Pipeline by e-Therapeutics Plc, H1 2015 141

Glioblastoma Multiforme (GBM)-Pipeline by Ecrins Therapeutics SAS, H1 2015 142

Glioblastoma Multiforme (GBM)-Pipeline by Eisai Co., Ltd., H1 2015 143

Glioblastoma Multiforme (GBM)-Pipeline by Eli Lilly and Company, H1 2015 144

Glioblastoma Multiforme (GBM)-Pipeline by EnGeneIC Ltd, H1 2015 145

Glioblastoma Multiforme (GBM)-Pipeline by EntreChem, S.L., H1 2015 146

Glioblastoma Multiforme (GBM)-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 147

Glioblastoma Multiforme (GBM)-Pipeline by ERC Belgium SA, H1 2015 148

Glioblastoma Multiforme (GBM)-Pipeline by Evotec AG, H1 2015 149

Glioblastoma Multiforme (GBM)-Pipeline by Exelixis, Inc., H1 2015 150

Glioblastoma Multiforme (GBM)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 151

Glioblastoma Multiforme (GBM)-Pipeline by FirstString Research, Inc., H1 2015 152

Glioblastoma Multiforme (GBM)-Pipeline by Galileo Research s.r.l., H1 2015 153

Glioblastoma Multiforme (GBM)-Pipeline by Genentech, Inc., H1 2015 154

Glioblastoma Multiforme (GBM)-Pipeline by Genor BioPharma Co., Ltd., H1 2015 155

Glioblastoma Multiforme (GBM)-Pipeline by GenSpera, Inc., H1 2015 156

Glioblastoma Multiforme (GBM)-Pipeline by GlaxoSmithKline Plc, H1 2015 157

Glioblastoma Multiforme (GBM)-Pipeline by GW Pharmaceuticals Plc, H1 2015 158

Glioblastoma Multiforme (GBM)-Pipeline by Hospira, Inc., H1 2015 159

Glioblastoma Multiforme (GBM)-Pipeline by Houston Pharmaceuticals, Inc., H1 2015 160

Glioblastoma Multiforme (GBM)-Pipeline by Hutchison MediPharma Limited, H1 2015 161

Glioblastoma Multiforme (GBM)-Pipeline by immatics biotechnologies GmbH, H1 2015 162

Glioblastoma Multiforme (GBM)-Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 163

Glioblastoma Multiforme (GBM)-Pipeline by Immunocore Limited, H1 2015 164

Glioblastoma Multiforme (GBM)-Pipeline by Immunomic Therapeutics, Inc., H1 2015 165

Glioblastoma Multiforme (GBM)-Pipeline by Immunovaccine, Inc., H1 2015 166

Glioblastoma Multiforme (GBM)-Pipeline by INSYS Therapeutics, Inc., H1 2015 167

Glioblastoma Multiforme (GBM)-Pipeline by InteRNA Technologies B.V., H1 2015 168

Glioblastoma Multiforme (GBM)-Pipeline by Intica Biomedical, Inc., H1 2015 169

Glioblastoma Multiforme (GBM)-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 170

Glioblastoma Multiforme (GBM)-Pipeline by Johnson & Johnson, H1 2015 171

Glioblastoma Multiforme (GBM)-Pipeline by Kadmon Corporation, LLC, H1 2015 172

Glioblastoma Multiforme (GBM)-Pipeline by Kalgene Pharmaceuticals Inc., H1 2015 173

Glioblastoma Multiforme (GBM)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 174

Glioblastoma Multiforme (GBM)-Pipeline by Kite Pharma, Inc., H1 2015 175

Glioblastoma Multiforme (GBM)-Pipeline by Lentigen Technology, Inc., H1 2015 176

Glioblastoma Multiforme (GBM)-Pipeline by Les Laboratoires Servier SAS, H1 2015 177

Glioblastoma Multiforme (GBM)-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 178

Glioblastoma Multiforme (GBM)-Pipeline by Mabion SA, H1 2015 179

Glioblastoma Multiforme (GBM)-Pipeline by MediGene AG, H1 2015 180

Glioblastoma Multiforme (GBM)-Pipeline by MedImmune, LLC, H1 2015 181

Glioblastoma Multiforme (GBM)-Pipeline by Merck & Co., Inc., H1 2015 182

Glioblastoma Multiforme (GBM)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 183

Glioblastoma Multiforme (GBM)-Pipeline by Nanobiotix, H1 2015 184

Glioblastoma Multiforme (GBM)-Pipeline by Nascent Biotech, Inc., H1 2015 185

Glioblastoma Multiforme (GBM)-Pipeline by Nemucore Medical Innovations, Inc., H1 2015 186

Glioblastoma Multiforme (GBM)-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 187

Glioblastoma Multiforme (GBM)-Pipeline by NewLink Genetics Corporation, H1 2015 188

Glioblastoma Multiforme (GBM)-Pipeline by Nexgenix Pharmaceuticals, LLC, H1 2015 189

Glioblastoma Multiforme (GBM)-Pipeline by Northwest Biotherapeutics, Inc., H1 2015 190

Glioblastoma Multiforme (GBM)-Pipeline by Novartis AG, H1 2015 191

Glioblastoma Multiforme (GBM)-Pipeline by Novogen Limited, H1 2015 192

Glioblastoma Multiforme (GBM)-Pipeline by Noxxon Pharma AG, H1 2015 193

Glioblastoma Multiforme (GBM)-Pipeline by Omniox, Inc., H1 2015 194

Glioblastoma Multiforme (GBM)-Pipeline by Oncobiologics, Inc., H1 2015 195

Glioblastoma Multiforme (GBM)-Pipeline by Oncodesign SA, H1 2015 196

Glioblastoma Multiforme (GBM)-Pipeline by Oncolytics Biotech Inc., H1 2015 197

Glioblastoma Multiforme (GBM)-Pipeline by Onconova Therapeutics, Inc., H1 2015 198

Glioblastoma Multiforme (GBM)-Pipeline by Oncovir, Inc., H1 2015 199

Glioblastoma Multiforme (GBM)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 200

Glioblastoma Multiforme (GBM)-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 201

Glioblastoma Multiforme (GBM)-Pipeline by Panacea Biotec Limited, H1 2015 202

Glioblastoma Multiforme (GBM)-Pipeline by Panacela Labs, Inc., H1 2015 203

Glioblastoma Multiforme (GBM)-Pipeline by Peloton Therapeutics, Inc., H1 2015 204

Glioblastoma Multiforme (GBM)-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 205

Glioblastoma Multiforme (GBM)-Pipeline by Pfizer Inc., H1 2015 206

Glioblastoma Multiforme (GBM)-Pipeline by PharmAbcine, Inc., H1 2015 207

Glioblastoma Multiforme (GBM)-Pipeline by PharmaCyte Biotech, Inc., H1 2015 208

Glioblastoma Multiforme (GBM)-Pipeline by Plexxikon Inc., H1 2015 209

Glioblastoma Multiforme (GBM)-Pipeline by Prana Biotechnology Limited, H1 2015 210

Glioblastoma Multiforme (GBM)-Pipeline by Progenics Pharmaceuticals, Inc., H1 2015 211

Glioblastoma Multiforme (GBM)-Pipeline by Regulus Therapeutics Inc., H1 2015 212

Glioblastoma Multiforme (GBM)-Pipeline by RestorGenex Corporation, H1 2015 213

Glioblastoma Multiforme (GBM)-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 214

Glioblastoma Multiforme (GBM)-Pipeline by Rigontec GmbH, H1 2015 215

Glioblastoma Multiforme (GBM)-Pipeline by Sagetis Biotech, S.L., H1 2015 216

Glioblastoma Multiforme (GBM)-Pipeline by Sanofi, H1 2015 217

Glioblastoma Multiforme (GBM)-Pipeline by Selvita SA, H1 2015 218

Glioblastoma Multiforme (GBM)-Pipeline by Siena Biotech S.p.A., H1 2015 219

Glioblastoma Multiforme (GBM)-Pipeline by Sigma-Tau S.p.A., H1 2015 220

Glioblastoma Multiforme (GBM)-Pipeline by Sirnaomics, Inc., H1 2015 221

Glioblastoma Multiforme (GBM)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 222

Glioblastoma Multiforme (GBM)-Pipeline by STELIS Biopharma Pvt. Ltd., H1 2015 223

Glioblastoma Multiforme (GBM)-Pipeline by Stemline Therapeutics, Inc., H1 2015 224

Glioblastoma Multiforme (GBM)-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 225

Glioblastoma Multiforme (GBM)-Pipeline by Terpenoid Therapeutics, Inc., H1 2015 226

Glioblastoma Multiforme (GBM)-Pipeline by Therapeia GmbH & Co. KG, H1 2015 227

Glioblastoma Multiforme (GBM)-Pipeline by Theravectys S.A., H1 2015 228

Glioblastoma Multiforme (GBM)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 229

Glioblastoma Multiforme (GBM)-Pipeline by Tocagen Inc., H1 2015 230

Glioblastoma Multiforme (GBM)-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 231

Glioblastoma Multiforme (GBM)-Pipeline by TVAX Biomedical, Inc., H1 2015 232

Glioblastoma Multiforme (GBM)-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 233

Glioblastoma Multiforme (GBM)-Pipeline by Vascular Biogenics Ltd., H1 2015 234

Glioblastoma Multiforme (GBM)-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 235

Glioblastoma Multiforme (GBM)-Pipeline by ViraTherapeutics GmbH, H1 2015 236

Glioblastoma Multiforme (GBM)-Pipeline by Virttu Biologics Limited, H1 2015 237

Assessment by Monotherapy Products, H1 2015 238

Assessment by Combination Products, H1 2015 239

Number of Products by Stage and Target, H1 2015 241

Number of Products by Stage and Mechanism of Action, H1 2015 256

Number of Products by Stage and Route of Administration, H1 2015 267

Number of Products by Stage and Molecule Type, H1 2015 269

Glioblastoma Multiforme (GBM) Therapeutics-Recent Pipeline Updates, H1 2015 760

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2015 1028

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..1), H1 2015 1029

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..2), H1 2015 1030

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..3), H1 2015 1031

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..4), H1 2015 1032

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..5), H1 2015 1033

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..6), H1 2015 1034

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..7), H1 2015 1035

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..8), H1 2015 1036

Glioblastoma Multiforme (GBM)-Dormant Projects (Contd..9), H1 2015 1037

Glioblastoma Multiforme (GBM)-Discontinued Products, H1 2015 1038

Glioblastoma Multiforme (GBM)-Discontinued Products (Contd..1), H1 2015 1039

Glioblastoma Multiforme (GBM)-Discontinued Products (Contd..2), H1 2015 1040

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2015 42

Number of Products under Development for Glioblastoma Multiforme (GBM)-Comparative Analysis, H1 2015 43

Number of Products under Development by Companies, H1 2015 44

Number of Products under Investigation by Universities/Institutes, H1 2015 58

Comparative Analysis by Late Stage Development, H1 2015 63

Comparative Analysis by Clinical Stage Development, H1 2015 64

Comparative Analysis by Early Stage Products, H1 2015 65

Assessment by Monotherapy Products, H1 2015 238

Assessment by Combination Products, H1 2015 239

Number of Products by Top 10 Targets, H1 2015 240

Number of Products by Stage and Top 10 Targets, H1 2015 240

Number of Products by Top 10 Mechanism of Actions, H1 2015 255

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 255

Number of Products by Top 10 Routes of Administration, H1 2015 266

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 266

Number of Products by Top 10 Molecule Types, H1 2015 268

Number of Products by Stage and Top 10 Molecule Types, H1 2015 268

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AbbVie Inc.

Actelion Ltd

Actinium Pharmaceuticals, Inc.

Actinogen Limited

Activartis Biotech GmbH

Aduro BioTech, Inc.

Advanced Accelerator Applications SA

Advanced Cancer Therapeutics

Advenchen Laboratories, LLC

Agenus, Inc.

AGY Therapeutics, Inc.

Amal Therapeutics SA

Ambrx, Inc.

Amgen Inc.

Ampio Pharmaceuticals, Inc.

AngioChem Inc.

Apogenix GmbH

Argon Pharma S.L.

Ariad Pharmaceuticals, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Axelar AB

Bexion Pharmaceuticals, LLC.

biOasis Technologies Inc.

BioCancell Ltd

Biomar Microbial Technologies

Bioncotech Therapeutics S.L.

Biovista Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

CalAsia Pharmaceuticals, Inc.

Cavion LLC

Celgene Corporation

Celldex Therapeutics, Inc.

Cellectis S.A.

Celltrion, Inc.

Celsion Corporation

ChemoCentryx, Inc.

CLL Pharma

Cold Genesys, Inc.

CTI BioPharma Corp.

CureFAKtor Pharmaceuticals, LLC

CureTech Ltd.

CytomX Therapeutics, Inc.

CytoVac A/S

CytRx Corporation

Deciphera Pharmaceuticals, LLC

DEKK-TEC, Inc.

Delenex Therapeutics AG

Diffusion Pharmaceuticals LLC

DiscoveryBiomed, Inc.

e-Therapeutics Plc

Ecrins Therapeutics SAS

Eisai Co., Ltd.

Eli Lilly and Company

EnGeneIC Ltd

EntreChem, S.L.

Epirus Biopharmaceuticals, Inc.

ERC Belgium SA

Evotec AG

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

FirstString Research, Inc.

Galileo Research s.r.l.

Genentech, Inc.

Genor BioPharma Co., Ltd.

GenSpera, Inc.

GlaxoSmithKline Plc

GW Pharmaceuticals Plc

Hospira, Inc.

Houston Pharmaceuticals, Inc.

Hutchison MediPharma Limited

immatics biotechnologies GmbH

ImmunoCellular Therapeutics, Ltd.

Immunocore Limited

Immunomic Therapeutics, Inc.

Immunovaccine, Inc.

INSYS Therapeutics, Inc.

InteRNA Technologies B.V.

Intica Biomedical, Inc.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Johnson & Johnson

Kadmon Corporation, LLC

Kalgene Pharmaceuticals Inc.

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

Lentigen Technology, Inc.

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings, Inc.

Mabion SA

MediGene AG

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Nanobiotix

Nascent Biotech, Inc.

Nemucore Medical Innovations, Inc.

Nerviano Medical Sciences S.r.l.

NewLink Genetics Corporation

Nexgenix Pharmaceuticals, LLC

Northwest Biotherapeutics, Inc.

Novartis AG

Novogen Limited

Noxxon Pharma AG

Omniox, Inc.

Oncobiologics, Inc.

Oncodesign SA

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

Oncovir, Inc.

Ono Pharmaceutical Co., Ltd.

Orphagen Pharmaceuticals, Inc.

Panacea Biotec Limited

Panacela Labs, Inc.

Peloton Therapeutics, Inc.

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

PharmAbcine, Inc.

PharmaCyte Biotech, Inc.

Plexxikon Inc.

Prana Biotechnology Limited

Progenics Pharmaceuticals, Inc.

Regulus Therapeutics Inc.

RestorGenex Corporation

Rexahn Pharmaceuticals, Inc.

Rigontec GmbH

Sagetis Biotech, S.L.

Sanofi

Selvita SA

Siena Biotech S.p.A.

Sigma-Tau S.p.A.

Sirnaomics, Inc.

Spectrum Pharmaceuticals, Inc.

STELIS Biopharma Pvt. Ltd.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Terpenoid Therapeutics, Inc.

Therapeia GmbH & Co. KG

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

Tocagen Inc.

TRACON Pharmaceuticals, Inc.

TVAX Biomedical, Inc.

Upsher-Smith Laboratories, Inc.

Vascular Biogenics Ltd.

Vertex Pharmaceuticals Incorporated

ViraTherapeutics GmbH

Virttu Biologics Limited

Glioblastoma Multiforme (GBM) Therapeutic Products under Development, Key Players in Glioblastoma Multiforme (GBM) Therapeutics, Glioblastoma Multiforme (GBM) Pipeline Overview, Glioblastoma Multiforme (GBM) Pipeline, Glioblastoma Multiforme (GBM) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com